122 related articles for article (PubMed ID: 35467089)
1. The influence of venetoclax, used alone or in combination with cladribine (2-CdA), on CLL cells apoptosis in vitro: Preliminary results.
Kubiak AB; Ziółkowska EI; Korycka-Wołowiec AB; Robak T; Wołowiec D
Adv Clin Exp Med; 2022 Sep; 31(9):1023-1033. PubMed ID: 35467089
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
Ann Hematol; 2010 Nov; 89(11):1115-24. PubMed ID: 20499237
[TBL] [Abstract][Full Text] [Related]
6. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R; Tian L; Anderson MA; Flensburg C; Jarratt A; Garnham AL; Jabbari JS; Peng H; Lew TE; Teh CE; Gouil Q; Georgiou A; Tan T; Djajawi TM; Tam CS; Seymour JF; Blombery P; Gray DHD; Majewski IJ; Ritchie ME; Roberts AW; Huang DCS
Blood; 2022 Nov; 140(20):2127-2141. PubMed ID: 35709339
[TBL] [Abstract][Full Text] [Related]
7. 2-Chloro-2'-deoxyadenosine-induced apoptosis in T leukemia cells is mediated via a caspase-3-dependent mitochondrial feedback amplification loop.
Conrad DM; Robichaud MR; Mader JS; Boudreau RT; Richardson AM; Giacomantonio CA; Hoskin DW
Int J Oncol; 2008 Jun; 32(6):1325-33. PubMed ID: 18497995
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
Ann Hematol; 2011 Feb; 90(2):173-83. PubMed ID: 20714724
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
Petersen AJ; Brown RD; Gibson J; Pope B; Luo XF; Schutz L; Wiley JS; Joshua DE
Eur J Haematol; 1996 Apr; 56(4):213-20. PubMed ID: 8641389
[TBL] [Abstract][Full Text] [Related]
11. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
12. 2-Chloro-2'-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes.
Van Den Neste E; Cardoen S; Husson B; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Leukemia; 2002 Jan; 16(1):36-43. PubMed ID: 11840261
[TBL] [Abstract][Full Text] [Related]
13. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
[TBL] [Abstract][Full Text] [Related]
14. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Stilgenbauer S; Morschhauser F; Wendtner CM; Cartron G; Hallek M; Eichhorst B; Kozloff MF; Giever T; Lozanski G; Jiang Y; Huang H; Pignataro DS; Schary W; Humphrey K; Mobasher M; Salles G
Haematologica; 2021 Nov; 106(11):2834-2844. PubMed ID: 33121235
[TBL] [Abstract][Full Text] [Related]
17. Frontline treatment in CLL: the case for time-limited treatment.
Lévy V; Delmer A; Cymbalista F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):59-67. PubMed ID: 34889444
[TBL] [Abstract][Full Text] [Related]
18. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
19. Cladribine in the treatment of chronic lymphocytic leukemia.
Robak T
Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB.
Smal C; Lisart S; Maerevoet M; Ferrant A; Bontemps F; Van Den Neste E
Biochem Pharmacol; 2007 Feb; 73(3):351-8. PubMed ID: 17137556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
